Disease · MONDO_0004993

carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinoma. Diseases, record MONDO_0004993. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004993

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinoma; Open Targets
Open Targets ID: MONDO_0004993; Open Targets
Other names: Other carcinoma, carcinoma, malignant, epithelial carcinoma, epithelioma, epithelioma malignant, malignant epithelial neoplasm, malignant epithelial tumor, malignant epithelial tumour, malignant epithelioma; Open Targets
Disease Ontology: DOID:305; Disease Ontology
MeSH: D002277; MeSH
NCI Thesaurus: C2916; NCI Thesaurus
Highest stage of its drugs: Approval, for 14 of its 44 drugs, from DailyMed and TTD; Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CINACALCET HYDROCHLORIDE	CHEMBL1200776	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ESTRAMUSTINE PHOSPHATE SODIUM	CHEMBL1200721	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
FLUTAMIDE	CHEMBL806	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
GADOPENTETATE DIMEGLUMINE	CHEMBL1200431	Small molecule	Approval	TTD	1	0	0	Drugs and targets
GOSERELIN ACETATE	CHEMBL1200501	Protein	Approval	DailyMed	1	0	0	Drugs and targets
HEXAMINOLEVULINATE HYDROCHLORIDE	CHEMBL1201785	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets84

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP1	DNA topoisomerase 1	4	DNA topoisomerase I inhibitor	Approval	https://conductscience.org/library/genes/7150	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
AR	Androgen receptor	2	Androgen Receptor antagonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 84

See all 84 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01295827	Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)	Phase 1	1,260	2019-12-13	Cancer, Solid Tumor	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00753675	Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	Phase 2	174	2013-11-28	Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma	GEMCITABINE, VANDETANIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00873119	Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary	Phase 2	89	2014-12-09	Carcinoma of Unknown Primary	BELINOSTAT, CARBOPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01684202	A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)	Phase 2	43	2021-03-18	Carcinomatous Edema	TOLVAPTAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00066781	Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary	Phase 2	31	2017-04-04	Carcinoma of Unknown Primary	GEMCITABINE, IRINOTECAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02939300	Ipilimumab and Nivolumab in Leptomeningeal Metastases	Phase 2	18	2022-11-14	Leptomeningeal Carcinomatosis	IPILIMUMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01593306	Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix	Phase 3	80		Carcinoma Cervix	CISPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT06505551	Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma	Phase 1/2	66		HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vaginal Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Head and Neck Cancer	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT01721148	A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours	Phase 1	39		Malignant Solid Tumour	BMS-777607	Its record names the disease	ClinicalTrials.gov
NCT00613691	A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma	Phase 1	36		Carcinoma	SOVATELITIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A - BelCaP vs Arm B - CaP: serious adverse events	22 of 42	10 of 44	86	NCT00873119	Trial comparisons
Cohort I vs Cohort II: serious adverse events	0 of 14	0 of 17	31	NCT00066781	Trial comparisons

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41894181	RESULT	1	PubMed
27117531	RESULT	1	PubMed
25977344	RESULT	1	PubMed
25034862	RESULT	1	PubMed
37816266	DERIVED	1	PubMed
37699333	DERIVED	1	PubMed
35101941	DERIVED	1	PubMed
34642329	DERIVED	1	PubMed
34571336	DERIVED	1	PubMed
33713216	DERIVED	1	PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004993

GET https://conductscience.org/api/diseases/v1/MONDO_0004993/drugs?page=2

API reference For AI assistants